Todays News

NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians in diagnostic cases using real historical medical charts. Built on the same HIPAA-compliant platform that powers live summarization of electronic health records (EHRs) in hospital settings, the simulation lets clinicians explore rare, complex cases from hundreds of years ago without patient risk. CEO Vince Hartman calls it “a Microsoft Flight Simulator for medicine,” enabling diagnostic training on authentic data with no need for EHR integration. “Three years after ChatGPT, fewer than 1% of physicians have ever seen an AI full medical record summary,” he says. “We’re changing that.” Each case begins with an AI-generated summary distilled from original, centuries-old handwritten documents. Clinicians explore the structured chart, from history of present illness to labs and vitals, and receive simulated updates based on actual clinical observations. “It’s not a quiz. It’s about engaging clinical reasoning in a sandbox where doctors can make decisions and learn from them,” Hartman explains. The simulation is built on Abstractive Health’s existing summarization and retrieval-augmented generation (RAG) and agentic AI platform. Leveraging advanced OCR and a robust AI summarization pipeline, it can also process handwritten records and turn scribbled notes into readable clinical narratives. The summarization technology is currently being piloted at Weill Cornell Medicine in a research collaboration to assist with writing Emergency Medicine handoff notes. Abstractive Health is also preparing to roll out the experience to Canadian outpatient clinics through a partnership with Canada’s WELL Health Technologies that followed an investment and distribution deal inked last year. Abstractive Health’s broader goal is to bring clinicians into meaningful, hands-on engagement with AI. “We’re not just saving time - we’re helping doctors think better,” Hartman says. “This is about curiosity, growth, and elevating clinical skill.” Clinical Time Machine is available now through Abstractive’s platform for free. About Abstractive Health Abstractive Health retrieves medical records, generates trusted AI summaries, and answers complex clinical questions. Its platform is used by clinicians nationwide and is currently in pilots with Well Health and Weill Cornell Medicine. A top 3 company in the 2024 VA AI Tech Sprint, Abstractive is backed by the NSF and has been featured by Forbes 30 Under 30. https://www.abstractivehealth.com Contacts Media Contact:Giordana Pulpo, giordana@abstractivehealth.com

MISSISSAUGA, Ontario--(BUSINESS WIRE)--VIQ Solutions Inc. (“VIQ”, “VIQ Solutions” or the “Company”) (TSX: VQS), a global provider of secure, AI-driven, digital voice and video capture technology and transcription services, announced the voting results from its annual general meeting of shareholders (the “Meeting”) on June 13, 2025. Shareholders approved all matters set forth in the Company’s management information circular dated May 1, 2025 (the “Circular”). A total of 16,990,031 common shares of the Company (“Shares”) were voted at the Meeting, representing 32.465% of the issued and outstanding Shares. The voting results for the election of directors were as follows: Nominee % of votes for % of votes withheld Sebastien Paré 97.025% 2.975% Larry Taylor 97.027% 2.973% Joseph Quarin 98.699% 1.301% Bradley Wells 98.898% 1.102% The voting results for the appointment of the auditors of the Company were as follows: Appointing Ernst & Young LLP, Chartered Professional Accountants, as auditor of the Company for the ensuing year and authorizing the board of directors of the Company to fix their remuneration: Votes for: 99.125% Votes withheld: 0.875% For further details on each of the above matters, please refer to the Circular available under VIQ’s profile on the System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca. Final voting results on all matters voted on at the Meeting will be filed on SEDAR+ at www.sedarplus.ca. For more information about VIQ, please visit viqsolutions.com. About VIQ Solutions VIQ Solutions is a global provider of secure, AI-driven, digital voice and video capture technology and transcription services. VIQ offers a seamless, comprehensive solution suite that delivers intelligent automation, enhanced with human review, to drive transformation in the way content is captured, secured, and repurposed into actionable information. The cyber-secure, AI technology and services platform are implemented in the most rigid security environments including criminal justice, legal, insurance, government, corporate finance, media, and transcription service provider markets, enabling them to improve the quality and accessibility of evidence, to easily identify predictive insights and to achieve digital transformation faster and at a lower cost. Contacts Media Contact: Jacob Manning Email: marketing@viqsolutions.com Phone: (800) 263-9947

TelevisaUnivision will leverage EDO’s investment-grade CTV outcomes to measure and optimize ad effectiveness on ViXNEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, and TelevisaUnivision, the world’s leading Spanish-language media company, have expanded their partnership to measure the consumer impact of TV ads on ViX, TelevisaUnivision’s global streaming service. This partnership builds on the existing framework that delivers data-driven TV insights designed to optimize advertiser ROI across TelevisaUnivision's cross-platform campaigns, now including ViX. TelevisaUnivision will receive EDO’s investment-grade TV intelligence to demonstrate the immense impact of a fast-growing, highly engaged Hispanic audience. According to EDO, ads on Spanish-language TV networks were 31% more effective than those on English-language TV in 2024, with leading brands like Walmart, Chevrolet, and Target achieving measurable engagement lifts by authentically integrating cultural relevance into their campaigns. “TelevisaUnivision’s deep connection with the Hispanic audience and culture, along with a growing content portfolio, makes them an ideal partner in today’s convergent TV landscape,” said Kevin Krim, President & CEO, EDO. “With EDO’s predictive outcome measurement, they can demonstrate the powerful consumer response their linear and streaming platforms drive and help brands immediately optimize for TV outcomes across campaigns.” “Brands need transparent and trusted insights into how their marketing investments perform among the most valuable growth segment: U.S. Hispanics. The reach and scale of TelevisaUnivision’s industry-leading programming continues to drive growth for brands,” said Dan Riess, Chief Operating Officer of U.S. Advertising Sales and Marketing at TelevisaUnivision. “With EDO’s outcomes data, we can quantify and optimize audience engagement across our portfolio, and most importantly, help brands understand the impact of investing in Hispanic audiences.” In May, TelevisaUnivision announced that ViX is delivering incremental audiences, reaching 28 million U.S. video viewers across platforms and increasing streaming hours per user by over 70% year-over-year, driven by its largest library of Spanish-language content. Early cross-platform outcomes on ViX, as measured by EDO, indicate strong consumer engagement. Discover the strategies advertisers are using to drive over 50% more consumer engagement with Spanish-language media and ViX. Join TelevisaUnivision and EDO on Thursday, June 26, for “Good, Better, and Best Approaches to Advertising with Impact.” For deeper insights on the power of Spanish-language TV advertising, check out EDO’s Spanish-language TV Outcomes Report. About EDO EDO is the TV outcomes company. Our leading measurement platform connects convergent TV airings to the ad-driven consumer behaviors most predictive of future sales. EDO empowers the advertising industry to maximize media impact, optimize creative performance, and know the fair value of every impression — across linear and streaming for an increasingly programmatic world. By combining immediate engagement signals with world-class decision science and vertical AI, EDO equips industry leaders with syndicated, investment-grade data that aligns media to business results — with detailed competitive, category, and historical insights. Leading brands, agencies, networks, streamers, and studios trust EDO’s TV intelligence to know what works. About TelevisaUnivision TelevisaUnivision is the world’s leading Spanish-language media company. Powered by the largest library of owned Spanish-language content and a prolific production capability, TelevisaUnivision is the top producer of original content in Spanish across news, sports and entertainment verticals. This original content powers all of TelevisaUnivision’s platforms, which include market-leading broadcast networks Univision, Las Estrellas, Canal 5 and UniMás, and a portfolio of 38 cable networks, which include TUDN, Galavisión, Distrito Comedia and TL Novelas. The company also operates the leading Mexican movie studio, Videocine, and owns and operates the largest Spanish-language audio platform in the U.S. across 35 terrestrial stations and the Uforia digital platform. TelevisaUnivision is also the owner of ViX, the largest Spanish-language streaming platform in the world. For more information, please visit televisaunivision.com. Contacts Media contacts KCSA for EDO edo@kcsa.com TelevisaUnivision Anna Negron anegron@televisaunivision.com

Study finds that CHAI (Computational Histology AI) biomarkers stratify recurrence and progression outcomes independently and outperform current guideline-based risk stratificationPALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights the performance and clinical impact of Valar Labs’ Vesta platform in prognosticating outcomes for patients with high grade Ta non muscle invasive bladder cancer, a population frequently on the borderline of guideline-based risk stratification who may receive different treatment depending on which guideline their provider uses. Bladder cancer treatment remains highly variable in its outcomes, with limited tools available to tailor therapies to individual patients. Valar Labs’ Vesta platform, built using advanced artificial intelligence, analyzes pathology to provide critical clinical insights. The newly published study demonstrates that Vesta Risk Stratify biomarkers accurately predicts recurrence and disease progression and outperforms existing guideline-based risk stratification, offering a transformative step forward in precision oncology for bladder cancer. Vesta allows for tailored management based on a patient’s individual risk. “HGTa tumors carry differing risks as current guidelines attempt to address, and clinical factors such as tumor focality and size can help delineate the true nature of these tumors. These clinical factors, however, are somewhat crude and can be misleading at times. This study demonstrated that CHAI biomarkers can offer improved and additional risk stratification that can go beyond traditional risk factors to better prognosticate outcomes in this population.” - Dr. Sam S. Chang, Chief Surgical Officer, Vanderbilt Ingram Cancer Center "The ability to derive clinically meaningful predictive and prognostic information from routinely-collected pathology is a paradigm shift for the risk stratification of bladder cancer patients." - Dr. Siamak Daneshmand, Professor of Urology and Medicine (Oncology), and Director of Urologic Oncology, University of Southern California The multi-center validation study was conducted in collaboration with leading academic centers and underscores both the reproducibility and robustness of the CHAI biomarkers. These findings further establish Vesta as a leading precision oncology platform in the management of non-muscle-invasive bladder cancer. “This publication is a testament to the clinical significance and scientific rigor of our work,” said Anirudh Joshi, CEO of Valar Labs. “Vesta’s prognostic and predictive tests represent a leap forward in precision medicine for bladder cancer—providing physicians and patients with data-driven insights to guide treatment decisions more effectively.” “This impactful work continues to build on Vesta’s evidence base as the leading predictive and prognostic biomarker portfolio in bladder cancer. We are excited for patients and providers to benefit from this technology,” said Viswesh Krishna, CTO of Valar Labs. Valar Labs continues to expand its suite of AI-driven diagnostic tests under the Vesta portfolio and beyond, aiming to improve outcomes across a range of cancers. For more information or to access the full study, please visit https://authors.elsevier.com/c/1lFoD14kpm0hjq. About Valar Labs Valar Labs is a precision medicine company developing computational histology AI diagnostic tests for predicting response to cancer therapies. Our mission is to provide every patient and physician the ability to select the best treatment based on the patient's tumor biology. Vesta is our portfolio of diagnostic tests that predicts which patients are unlikely to benefit from BCG therapy and provides detailed risk stratification for recurrence and progression. Vesta BCGPredict and Vesta Risk Stratify HG are clinically available through our CLIA-certified laboratory in Houston, Texas and can be ordered online. For more information, please visit www.valarlabs.com and follow us on LinkedIn and X. Contacts Media Relations +1 (888) 862-0232 media@valarlabs.com

DUBLIN--(BUSINESS WIRE)--The "Europe Spinal Navigation Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering. The Europe spinal navigation market was valued at $192.1 million in 2023 and is expected to reach $754.7 million by 2032, registering a CAGR of 16.42% during the forecast period 2023-2032. The market for spinal navigation in Europe includes cutting-edge guidance systems that help surgeons perform spine surgeries by showing the patient's anatomy in three dimensions in real time. These technologies, which include augmented reality headsets, AI-driven software overlays, optical and electromagnetic trackers, and more, are designed to improve surgical accuracy, lower intraoperative risks, and speed up recovery. The need for minimally invasive procedures has increased recently because to the growing prevalence of degenerative disc disease, spinal stenosis, and traumatic injuries in an ageing European population, making navigation technology essential tools for modern practice. With the use of advanced instruments that increase procedural accuracy, enhance patient safety, and produce better clinical results, the spinal navigation market in Europe is quickly changing the face of spine surgery. However, the high initial investment and continuing maintenance costs of these platforms continue to limit their widespread adoption throughout EU healthcare systems. Expanding access and providing patients across Europe with high-quality care will depend on overcoming these financial obstacles through creative funding models, advantageous reimbursement schemes, and cooperative procurement tactics. Integrated operating-room suites, where navigation systems seamlessly connect with robotic arms and imaging modalities (CT, fluoroscopy, intraoperative MRI) to provide multifunctional capabilities, are becoming more and more common in hospitals and ambulatory surgical centres. In order to overcome financial limitations, equipment-as-a-service and shared-service procurement models have surfaced, allowing smaller institutions to access state-of-the-art platforms without having to make significant capital expenditures. However, due to a variety of national legislation, complicated payment procedures, and the requirement for substantial staff training, adoption is still unequal. Manufacturers are concentrating on enhancing tracking precision, optimising user interfaces, and incorporating predictive analytics to foresee intraoperative difficulties in the future. To broaden reimbursement systems and harmonise standards, OEMs, payers, and healthcare providers must cooperate together. The market for spinal navigation in Europe is expected to increase steadily as clinical proof of better patient outcomes and cost-effectiveness mounts, spurring advancements in spine surgery and wider surgical navigation applications. Europe Spinal Navigation Market Trends, Drivers and Challenges: Trends Increasing integration of AI-driven algorithms and augmented/virtual reality overlays to provide real-time, 3D intraoperative guidance. Convergence of robotic-assisted systems with traditional optical and electromagnetic navigation platforms, creating multifunctional operating suites. Growth of shared-service procurement and equipment-as-a-service models, enabling hospitals and surgical centres to spread capital expenditures and access the latest systems without large upfront investments. Drivers Europe's aging population and rising incidence of degenerative spinal conditions are driving demand for precise, minimally invasive procedures that reduce hospital stays and complication rates. Emphasis on patient safety and outcome-based reimbursement is accelerating adoption of navigation tools that minimise radiation exposure and improve surgical accuracy. Continuous technological advances - in tracking accuracy, user interfaces and data analytics - are enhancing surgeon confidence and expanding clinical applications beyond routine procedures. Challenges High initial purchase prices and ongoing maintenance expenses strain healthcare budgets, especially under tight reimbursement caps across different EU member states. Diverse, country-specific regulatory requirements and inconsistent reimbursement frameworks impede pan-European rollout and create market entry complexities. Integrating advanced navigation systems into existing OR infrastructures requires significant workflow adjustments and dedicated staff training, slowing adoption in smaller hospitals and outpatient centres. Key Attributes: Report Attribute Details No. of Pages 87 Forecast Period 2023 - 2032 Estimated Market Value (USD) in 2023 $192.1 Million Forecasted Market Value (USD) by 2032 $754.7 Million Compound Annual Growth Rate 16.4% Regions Covered Europe Key Topics Covered: 1 Executive Summary 2 Market Definition and Scope 3 Research Methodology 4 Regulatory Scenario and Device Classification 4.1 Regulatory Scenario in the EU 4.2 Regulatory Scenario in the U.K. 5 Reimbursement Scenario 5.1 Reimbursement Scenario in the U.K. 6 Procedure Volume of Spinal Conditions 7 Spinal Navigation Market (by Region) 7.1 Europe Spinal Navigation Market (by End User) 7.2 Europe Spinal Navigation Market, Installed Base (by End User) 7.3 U.K. Spinal Navigation Market 7.4 Germany Spinal Navigation Market 7.5 France Spinal Navigation Market 7.6 Italy Spinal Navigation Market 7.7 Spain Spinal Navigation Market 7.8 Austria Spinal Navigation Market 7.9 Rest-of-Europe Spinal Navigation Market 8 Hospital Profiles 9 Company Profiles 9.1 ERGOSURG GmbH 9.2 Brainlab AG 9.3 Siemens Healthineers AG 9.4 B. Braun 9.5 Joimax GmbH 9.6 RIWOspine GmbH Companies Featured ERGOSURG GmbH Brainlab AG Siemens Healthineers AG B. Braun Joimax GmbH RIWOspine GmbH  For more information about this report visit https://www.researchandmarkets.com/r/vtgnzl About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900